Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhu, Yan ^a   Tian, Tiantian ^a   Li, Zhongwu ^a   Tang, Zhiyu ^b   Wang, Lai ^b   Wu, Jian ^c   Li, Yilin ^a   Dong, Bin ^a   Li, Yanyan ^a   Li, Na ^a   Zou, Jianling ^a   Gao, Jing ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b Zhong Guan Cun Life Science Park   (China)

^c MyGenostics Inc   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; FEMALE; GASTROSCOPY; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; STOMACH TUMOR; TUMOR CELL CULTURE; VERY ELDERLY; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GASTROSCOPY; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; STOMACH NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 84923677416     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08542     Document Type: Article

References (39)

1. Hohenberger, P. & Gretschel, S. Gastic cancer. The Lancet 362, 305-315 (2003).
2. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-97 (2010).
3. Wadhwa, R., Taketa, T., Sudo, K., Blum-Murphy, M. & Ajani, J. A. Ramucirumab: a novel antiangiogenic agent. Future Oncol 9, 789-95 (2013).
4. Li, J. et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 31, 3219-25 (2013).
5. Suggitt, M. & Bibby, M. C. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11, 971-81 (2005).
6. Siolas, D.&Hannon,G. J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 73, 5315-9 (2013).
7. Sausville, E. A. & Burger, A. M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66, 3351-4, discussion 3354 (2006).
8. De Witt Hamer, P. C. et al. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27, 2091-6 (2008).
9. Daniel, V. C. et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 69, 3364-73 (2009).
10. Fichtner, I. et al. Anticancer drug response and expression ofmolecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40, 298-307 (2004).
11. Grisanzio, C. et al. Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol 225, 212-21 (2011).
12. Scott, C. L., Becker, M. A., Haluska, P. & Samimi, G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol 3, 295 (2013).
13. Wang, Y. et al.Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 64, 149-59 (2005).
14. Dong, X. et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res 16, 1442-51 (2010).
15. DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17, 1514-20 (2011).
16. Bock, B. C., Stein, U., Schmitt, C. A. & Augustin, H. G. Mouse models of human cancer. Cancer Res 74, 4671-5 (2014).
17. Linnebacher, M. et al. Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer 10, 362 (2010).
18. Spreafico, A. et al. Rational combination of aMEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res 19, 4149-62 (2013).
19. Marangoni, E. et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13, 3989-98 (2007).
20. Cutz, J. C. et al. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of 1primary human lung cancers: potential models for studying tumor progressionrelated changes. Clin Cancer Res 12, 4043-54 (2006).
21. Sivanand, S. et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med 4, 137ra75 (2012).
22. Yoshiyuki, T. et al. Immunohistochemical demonstration of epidermal growth factor in human gastric cancer xenografts of nude mice. Cancer 65, 953-7 (1990).
23. Kubota, T. et al. Growth of human tumor xenografts in nude mice and mice with severe combined immunodeficiency (SCID). Surg Today 23, 375-7 (1993).
24. Zhang, L. et al. A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. Sci Rep 3, 2992 (2013).
25. Jin, K. et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 12, 473-80 (2010).
26. Yamashita-Kashima, Y. et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 17, 5060-70 (2011).
27. Piazuelo, M. B. & Correa, P. Gastric cancer: Overview. Colomb Med (Cali) 44, 192-201 (2013).
28. Van Cutsem, E. et al.HER2 screening data from ToGA: targeting HER2 in gast-ric and gastroesophageal junction cancer. Gastric Cancer (2014) doi:10.1007/s10120-014-0402-y.
29. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
30. Julien, S. et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 18, 5314-28 (2012).
31. Spackman, E. et al. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer: a NICE single technology appraisal. Pharmacoeconomics 31, 185-94 (2013).
32. Ieni, A. et al.Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation. Onco Targets Ther 7, 1267-72 (2014).
33. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-9 (2013).
34. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-58 (2013).
35. Mardis, E. R. The impact of next-generation sequencing technology on genetics. Trends Genet 24, 133-41 (2008).
36. Liu, L. et al. Comparison of next-generation sequencing systems. J Biomed Biotechnol 2012, 251364 (2012).
37. Kodera, Y. et al. Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts. In Vivo 19, 861-6 (2005).
38. Sawada, N., Kondoh, K. & Mori, K. Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts. Oncol Rep 18, 775-8 (2007).
39. Tanizaki, J. et al. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther 9, 1198-207 (2010).